
COMBINED HORMONAL CONTRACEPTIVES (CHCs)

This decision support tool (DST) provides clinical guidance for the provision of combined hormonal contraception. It is meant to be used in concert with the [Contraceptive Management: Assessment DST](#).

DEFINITION

Contraception that contains both estrogen and progestin. Three types of combined hormonal contraception are available in Canada: oral contraceptive pills, the transdermal contraceptive patch and the intravaginal contraceptive ring

INDICATIONS

For the purpose of contraceptive management certified practice, CHCs are indicated for any client seeking a reliable, reversible, coitally-independent method of contraception. RN(C)s independently dispense or administer only CHCs that provide a daily dose of less than 50 mcg of ethinyl estradiol.

RN(C)s only dispense CHCs for the purpose of contraception. Clients seeking or using CHCs for a sole purpose other than contraception must be referred to a physician or nurse practitioner (NP) for a client specific order or transfer of care.

ACTION

The primary method of action of CHCs is through the suppression of gonadotropins induced by the estrogen and progestin effects on the hypothalamic/pituitary axis, thereby inhibiting ovulation. Progestin suppresses luteinizing hormone (LH) secretions, thereby eliminating the LH surge while estrogen suppresses follicle stimulating hormone (FSH) secretion, thereby decreasing follicular maturation. Other mechanisms of action may include the development of endometrial atrophy, making the endometrium unreceptive to implantation and cervical mucus changes that impede sperm transport.

PHARMACOKINETICS

Dose

Combined hormonal contraception contains ethinyl estradiol (EE) and a progestin in various doses and combinations. The amount of EE in CHCs vary. The amount and type of progestin vary and differ in potency and metabolic effect. A low-dose CHC preparation is preferred to provide effective contraception, acceptable cycle control and the least amount of side effects for that individual. CHCs providing a daily dose of 50 mcg or less of ethinyl estradiol are considered low-dose.

BCCNP monitors and revises the BCCNP certified practice decision support tools (DSTs) every two years and as necessary based on best practices. The information provided in the DSTs is considered current as of the date of publication. BCCNP-certified nurses (RN(C)s) are responsible for ensuring they refer to the most current DSTs.

The DSTs are not intended to replace the RN(C)'s professional responsibility to exercise independent clinical judgment and use evidence to support competent, ethical care. The RN(C) must consult with or refer to a physician or nurse practitioner as appropriate, or whenever a course of action deviates from the DST.

THIS DST IS FOR USE BY REGISTERED NURSES CERTIFIED BY BCCNP

© BCCNP February 2020/Pub. 717

Oral CHC Formulations

Oral CHCs are taken daily, at the same time each day. There are a range of different formulations of oral CHCs available, for example 21-7, 24-4 or extended use packaging.

- Monophasic (each tablet contains a fixed amount of estrogen and progestin)
- Biphasic (each tablet contains a fixed amount of estrogen; the amount of progestin increases in the second half of the cycle)
- Triphasic (the amount of estrogen can be fixed or variable; the amount of progestin increases in three equal phases)

Transdermal CHC Formulations

The transdermal patch is changed once a week for three weeks followed by one week patch-free.

Each transdermal contraceptive patch contains ethinyl estradiol 0.6 mg and norelgestromin 6 mg [releases approximately ethinyl estradiol 35 mcg and norelgestromin 200 mcg per 24 hours]

Intravaginal CHC Formulations

The intravaginal contraceptive ring is worn inside the vagina for three weeks followed by one week ring free.

- Each intravaginal ring delivers ethinyl estradiol 15 mcg/day and etonogestrel 120 mcg/day

Onset

Peak serum concentrations of combined estrogen and progestin vary between products. Contraceptive benefits are realized within seven days of consistent and correct CHC use.

CONSULT OR REFERRAL

RN(C)s are restricted to dispensing or administering CHCs to clients who classify as category 1 or 2 as defined by the *U.S. Medical Eligibility Criteria for Contraceptive Use*. RN(C)s cannot independently dispense or administer CHCs to women who classify as a category 3 or 4 without an order.

Relative Contraindications

As per *U.S. Medical Eligibility Criteria for Contraceptive Use*, Category 3

Absolute Contraindications

As per *U.S. Medical Eligibility Criteria for Contraceptive Use*, Category 4

RN(C)s must refer or consult with a physician or nurse practitioner for the following clients:

- Clients wanting to use CHCs in the presence of relative or absolute contraindications (*U.S. Medical Eligibility Criteria for Contraceptive Use*, categories 3 and 4).

- Clients whose medical condition has changed so that they might be using combined hormonal contraception in the presence of relative or absolute contraindications (*U.S. Medical Eligibility Criteria for Contraceptive Use*, categories 3 and 4).
- Clients with chronic health conditions that increase serum potassium or clients taking medications that increase serum potassium if considering use of a drospirenone containing CHC.
- Clients who are currently taking CHCs and demonstrate any of the following symptoms: ACHES (abdominal pain, chest pain, headache, eye problems and severe leg pain); unexplained vaginal bleeding; jaundice; syncope; blood pressure >140/>90; severe migraine headaches (with aura); severe depression; and/or severe allergic skin rash.
- Transvaginal ring users with a history of toxic shock syndrome (TSS). (Rare cases of TSS have been reported by ring users. Causation has not been determined.)
- Clients reporting headaches that are new and or worsening with the use of hormonal contraception
- Clients taking medications that might be affected by hormonal contraception

Drug Interactions

The following drugs and drug classes are considered MEC category 3 or 4 and could have some effect on CHC absorption. RN(C)s must refer or consult with a physician or nurse practitioner for clients taking any of the following:

- Anticonvulsants: phenytoin, carbamazepine, barbiturates, primidone, topiramate, oxcarbazepine. Lamotrigine alone (lamotrigine/valproate combo does not interact with hormones).
- Antimicrobials: Rifampicin or Rifabutin therapy

Note: Except for rifampicin, antibiotic use does not affect CHC efficacy.

Fosamprenavir (antiretroviral).

Drugs that may be affected by CHC use (consult or refer to physician or NP for appropriate management of these clients):

- Clients taking theophylline, tricyclic antidepressants, diazepam or lithium may need dosage adjustments.
- Drospirenone may increase potassium. Clients should be advised to inform their healthcare provider if they have kidney, liver or adrenal disease because the use of Drospirenone containing CHCs in the presence of these conditions could cause serious heart and health problems. They should also inform their healthcare provider if they are currently on daily, long-term treatment (NSAIDs, potassium-sparing diuretics, potassium supplementation,

ACE inhibitors, angiotensin-II receptor antagonists, heparin or aldosterone antagonists) for a chronic condition or taking strong CYP3A4 inhibitors.

PREGNANCY AND BREAST/CHEST FEEDING

Pregnancy

There is no known harm to the person, the course of the pregnancy or the fetus if CHCs are inadvertently used during pregnancy. However, if a CHC is inadvertently initiated with a pregnant client or the client becomes pregnant during CHC use, the CHC should be discontinued immediately.

Postpartum

Initiation of CHC in the post-partum period is dependent on level of risk. A summary is provided but a detailed breakdown can be reviewed in the most upto-date U.S. Selected Practice Recommendations for Contraceptive Use (US SPR).

MEC Category 4

- Less than 21 days post-partum

MEC Category 3

- Breast/chest feeding: 21 to < 30 Days
- Breast/chest feeding: 30–42 days postpartum with other risk factors for VTE (e.g., age ≥ 35 years, previous VTE, thrombophilia, immobility, transfusion at delivery, peripartum cardiomyopathy, BMI ≥ 30 kg/m², postpartum haemorrhage, postcesarean delivery, preeclampsia, or smoking)
- Non Breast/chest feeding: 21–42 days postpartum with other risk factors for VTE (e.g., age ≥ 35 years, previous VTE, thrombophilia, immobility, transfusion at delivery, peripartum cardiomyopathy, BMI ≥ 30 kg/m², postpartum hemorrhage, postcesarean delivery, preeclampsia, or smoking)

Breast/Chest feeding

Conflicting studies suggest theoretical concerns about the effects of CHCs on breastmilk volume. Estrogen and progestin are both excreted in breastmilk in small quantities, but are unlikely to have an effect on the baby.

PRECAUTIONS AND CONSIDERATIONS

In general for all combined Hormonal Contraceptives, the risk of VTE is highest in the first year of CHC use and in first-time users. The risk of VTE in CHC users remains significantly less than the risk of VTE

in pregnancy and the post-partum period. In the absence of symptoms, routine laboratory screening for thrombophilia or other bleeding disorders is not recommended.*

Precautions and Considerations Specific to the Oral Contraceptive Pill

- Malabsorption related to chronic gastrointestinal inflammation and active diarrhea might cause ineffectiveness of any oral contraception.
- Repeated vomiting (e.g., bulimia) and/or severe diarrhea can decrease the absorption of the pill and might decrease its effectiveness. Vomiting within two hours of pill ingestion might require repeated doses.
- The effectiveness of oral CHCs might be slightly decreased among clients who are obese (BMI >30). However, no association has been found between pregnancy risk and body mass index (BMI). It is likely that even a small decrease in effectiveness in clients who are obese still confers overall effectiveness to be high

Precautions and Considerations Specific to the Transdermal Contraceptive Patch

- The effectiveness of the patch might be slightly decreased among clients weighing greater than 90 kg or who are obese (BMI >30). However, no association has been found between pregnancy risk and body mass index (BMI). It is likely that even a small decrease in effectiveness in clients who are obese still confers overall effectiveness to be high and therefore should not be a reason to avoid this method.
- Clients with conditions that affect the skin, such as eczema, psoriasis, cuts, rash or sunburn, should not apply the patch to these areas.

Precautions and Considerations Specific to the Intravaginal Contraceptive Ring

- Clients who have significant pelvic relaxation, vaginal stenosis or utero-vaginal prolapse and are unable to touch their genitalia or who have vaginal obstruction are not good candidates for the intravaginal ring.
- Might not be suitable for clients who have conditions that make the vagina more susceptible to irritation or ulceration. Women who have genital outbreaks of herpes simplex virus are able to use the intravaginal contraceptive ring.
- Should not be used in conjunction with the diaphragm as it could dislodge this barrier.

* CHCs should not be withheld from women with a family history of venous thromboembolism (VTE) unless they demonstrate symptoms of VTE. Family history of VTE in a first degree relative is a category 2. Some thrombophilia conditions that increase the risk for a deep vein thrombosis (DVT) or pulmonary embolism are heritable. Testing for underlying thrombophilias might be indicated for women with a personal family history of VTE in a first degree relative with a history of spontaneous VTE (i.e., not associated with pregnancy, cancer, airline travel, surgery, obesity, immobilization etc). Screening of asymptomatic women is not recommended.

ADVERSE EFFECTS

Side effects from CHCs are often mild and transient and can respond to a change in formulation. Acknowledgment and management of side effects are crucial to successful continuation of CHCs.

A theoretical understanding of the different side effects implicated by hormones is helpful. The Society of Obstetricians and Gynecologists of Canada (SOGC) or the US MEC Selected Practice Recommendations for Hormonal Contraceptive Use (2016) have resources for understanding side effects related to contraceptives that can be used as a resource for health care providers.

Common Possible Side Effects

Common side effects of CHCs include, but are not limited to:

- Absence of withdrawal bleed
- Appetite changes (can result in weight gain)
- Breast tenderness
- Breakthrough bleeding/spotting
- Headaches (mild, without aura)
- Nausea
- Mood changes
- Libido changes
- Skin changes

Warning and Precautions

Serious side effects from CHCs are rare. The following symptoms should be investigated immediately, referred to a physician or nurse practitioner and might warrant discontinuation of CHCs:

- ACHES (abdominal pain, chest pain, headache, eye problems and severe leg pain)
- Moderate to Severe Depression
- Jaundice
- Unexplained vaginal bleeding
- Syncope
- Blood pressure >140/>90
- Severe or worsening migraine headaches with or without aura
- Severe allergic reaction

CLIENT EDUCATION SPECIFIC TO CHC USE

Missed or Late CHC Doses

If available, advise the client to follow the product monograph, or advise the client to contact a health care provider or clinic. Some clinics choose to develop client hand-outs or resources specific to missed or late

CHC doses. The Society of Obstetricians and Gynecologists of Canada (SOGC) or the US MEC Selected Practice Recommendations for Hormonal Contraceptive Use (2016) have guidelines for missed hormonal contraceptives that can be used as a resource for health care providers.

Continuous Use, Extended Use and Shortened Hormone Free Intervals

- When determining CHC method of use, the RN(C)s should discuss continuous use, extended use and shortened hormone free intervals with the client.
- All oral, transdermal and vaginally administered CHCs can be used as continuous, extended use and/or with shortened hormone free intervals.
- Continuous use, extended use and shortened hormone free intervals increase contraceptive efficacy
- The rate of side effects and adverse events with continuous use regimes is similar to conventional CHC use.

The length of the continuous use or extended use of combined hormonal contraceptive CHC regimens should be administered according to the preference of the client.

Common Side Effects of Continuous and Extended Use

The most common side effect of continuous and extended use of CHCs is irregular bleeding or spotting. This might result in higher discontinuation rates than 28-day CHC regimes or shortened hormone free interval regimes. Counselling clients on managing these side effects and informing them that the unscheduled bleeding will decrease over time is important.

DISPENSING

For dispensing CHCs, refer to the see [Contraceptive Management: Assessment DST](#)

The intravaginal contraceptive ring is a cold chain medication. Once the cold chain has been broken, it is stable at room temperature for up to four months. The “insert by” expiry date should be indicated on the package as soon as cold-chain storage is broken.

MANAGEMENT AND FOLLOW UP

- After initiation or change of a CHC:
 - Advise a client to return at any time to discuss side effects or other problems or if they want to change the method being used. No routine follow-up visit is required.
- Specific populations that might benefit from more frequent follow-up visits include adolescents, those with certain medical conditions or characteristics, and those with multiple medical conditions.
- At other routine visits, when seeing combined hormonal contraceptive users RN (C)s should do the following:

- Assess the client's satisfaction with their contraceptive method and whether they have any concerns about method use.
- Assess any changes in health status, including medications that would change the appropriateness of combined hormonal contraceptives for safe and effective continued use based on U.S. MEC (e.g., category 3 and 4 conditions and characteristics).
- Assess blood pressure (at least annually).
- Consider assessing weight changes and counselling women who are concerned about weight changes perceived to be associated with their contraceptive method.

DOCUMENTATION

- Refer to [Contraceptive Management: Assessment DST](#)


Appendix 1: CHC Screening Tool

This does not replace the most current practice recommendations, RN (C)s should always check medical eligibility against the most current US MEC.

Are there any relative or absolute contraindications for Combined Hormonal Contraceptive Use?		
Questions to assist in determining Medical Eligibility for CHC use:		
Have you ever been told you have breast cancer?	NO	YES
Have you ever had a stroke or problems with your heart?	NO	YES
Have you ever had a blood clot in your leg or lungs?	NO	YES
Have you ever been told you have a bleeding disorder?	NO	YES
Have you ever been told you have gall bladder disease, liver disease or jaundice?	NO	YES
Have you ever been told you have diabetes?	NO	YES
Have you ever been told you have lupus?	NO	YES
Have you ever been told you have high blood pressure or high cholesterol?	NO	YES
Have you ever had an organ transplant?	NO	YES
Do you have problems with severe diarrhea, poor absorption or other bowel disorders?	NO	YES
Do you get migraine headaches?	NO	YES
Are you planning any major surgery in the next 6 months?	NO	YES
Do you smoke cigarettes?	NO	YES
Have you been pregnant in the past 42 days?	NO	YES
Are you currently breastfeeding?	NO	YES
Do you take any medications including natural remedies?	NO	YES
Do you take anti-retroviral medications?	NO	YES
Do you take medications for seizures?	NO	YES
Do you take medications for tuberculosis?	NO	YES

IF YES to any:
STOP – EXPLORE OR REFER
 Client may not be a good candidate for CHC. Counsel about other contraceptive methods or consult/refer to Dr/NP if client is a MEC category 3 or 4.

IF YES to any:
CAUTION - EXPLORE
 Further assessment required. Evaluate client condition. If client is MEC category 3 or 4 consult/refer to Dr/NP.



REFERENCES

More recent editions of any of the items in the Reference List may have been published since this DST was published. If you have a newer version, please use it.

Anderson, K.C., Schwartz, M.D. and Lieu, S.O. (2013). Antibiotics and OC effectiveness. *Journal of the American Academy of Physician Assistants*, 26(1)11.

Blanco-Molina, A. and Montreal, M. (2010). Venous thromboembolism in women taking hormonal contraceptives. *Expert Review of Cardiovascular Therapy*, 8(2): 211-215.

Centers for Disease Control and Prevention. (2016). *U.S. medical eligibility criteria for contraceptive use, 2016. Morbidity and Mortality Weekly Report*, 65(3), 1-106. Retrieved from <https://www.cdc.gov/mmwr/volumes/65/rr/pdfs/rr6503.pdf>

Centers for Disease Control and Prevention. (2011). Update to CDC's U.S. medical eligibility criteria for contraceptive Use, 2010: Revised recommendations for the use of contraceptive methods during the postpartum period. *Morbidity and Mortality Weekly Report* 60(26):878–883. Retrieved from http://www.cdc.gov/mmwr/preview/mmwrhtml/mm6026a3.htm?s_cid=mm6026a3_w

Dickey, R. P. (2014). *Managing contraceptive pill patients* (15th ed.). Fort Collins, CO: E. M. I. S. Medical Publishing.

Grossman Barr, N. (2010). Managing Adverse Effects of Hormonal Contraceptives. *American Family Physician*, 82(12), 1499–1506.

Hatcher, R.A., Nelson, A.L., Trussell, J., Cwiak, C., Cason, P., Policar, M.S., Aiken, A.R.A., Marrazzo, J. & Kowal, D. (2019). *Contraceptive technology* (21st. ED.). Atlanta: Managing Contraception, LLC.:GA

Martinez, F., Ramirez, I., Perez-Campos, E., Latorre, K. and Lete, I. (2012). Venous and pulmonary thromboembolism and combined hormonal contraceptives. Systematic review and meta-analysis.

Rott, H. (2012). Thrombotic risks of oral contraceptives. *Current Opinion in Obstetrics and Gynecology*, 24. 235-240

Sridhar, A. & Salcedo, J. (2017). Optimizing maternal and neonatal outcomes with postpartum contraception: impact on breastfeeding and birth spacing. *Maternal Health, Neonatology and Perinatology*. 3:1 <https://doi.org/10.1186/s40748-016-0040-0>-Society of Obstetricians and Gynaecologists of Canada. (2015). *SOGC Clinical practice guidelines: Canadian contraception consensus (Part 1 to 4)*. Retrieved from <http://sogc.org/wp-content/uploads/2015/11/gui329Pt1CPG1510E.pdf>

Stewart, M. & Black, K. (2015). Choosing a combined oral contraceptive pill. *Aust Prescr* 2015:38:6-11.

World Health Organization. (2015). Medical eligibility criteria for contraceptive use, 5th Edition.
Retrieved from http://www.who.int/reproductivehealth/publications/family_planning/MEC-5/en/WHO.

Zieman, M., Hatcher, R. A., Allen, A. Z., Lathrop, E. & Haddad, L. (2017-2018). *Managing contraception on the go* (14th ed). Atlanta, GA: Bridging the Gap Communications